Macek Jilkova, Zuzana <br/><br/>
Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.  [electronic resource] 

 -  Clinical and translational gastroenterology  07 2019 
 - e00058 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2155-384X 
<br/><br/><label>Standard No.: </label>10.14309/ctg.0000000000000058  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antigens, CD--drug effects<br/>CD4-Positive T-Lymphocytes--drug effects<br/>CD8-Positive T-Lymphocytes--drug effects<br/>Carcinoma, Hepatocellular--drug therapy<br/>Disease Progression<br/>Female<br/>Hepatitis A Virus Cellular Receptor 2--drug effects<br/>Humans<br/>Immunotherapy--methods<br/>Liver Neoplasms--pathology<br/>Male<br/>Neoplasm Staging--methods<br/>Predictive Value of Tests<br/>Prognosis<br/>Programmed Cell Death 1 Receptor--antagonists & inhibitors<br/>Protein Kinase Inhibitors--therapeutic use<br/>Sorafenib--therapeutic use<br/>Up-Regulation<br/>Lymphocyte Activation Gene 3 Protein